146 related articles for article (PubMed ID: 31025329)
1. Confirmed case of Pneumocystis pneumonia in a Maltese Terrier × Papillon dog being treated with toceranib phosphate.
Best MP; Boyd SP; Danesi P
Aust Vet J; 2019 May; 97(5):162-165. PubMed ID: 31025329
[TBL] [Abstract][Full Text] [Related]
2. Skin depigmentation associated with toceranib phosphate in a dog.
Cavalcanti JVJ; Hasbach A; Barnes K; Dange RB; Patterson J; Saavedra PV
Vet Dermatol; 2017 Aug; 28(4):400-e95. PubMed ID: 28164401
[TBL] [Abstract][Full Text] [Related]
3. Toceranib phosphate-associated nephrotic syndrome in a dog: a case report.
Remerowski SM; Herrera CL; Donnelly LL
BMC Vet Res; 2021 Apr; 17(1):146. PubMed ID: 33827545
[TBL] [Abstract][Full Text] [Related]
4. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
[TBL] [Abstract][Full Text] [Related]
5. Effects of Toceranib Phosphate on Systolic Blood Pressure and Proteinuria in Dogs.
Tjostheim SS; Stepien RL; Markovic LE; Stein TJ
J Vet Intern Med; 2016 Jul; 30(4):951-7. PubMed ID: 27149912
[TBL] [Abstract][Full Text] [Related]
6. Plasma cytokeratin-18 concentrations as noninvasive biomarker of early gastrointestinal toxicosis in dogs receiving toceranib.
Kovac RL; Ballash G; Fenger J; London C; Warry E
J Vet Intern Med; 2018 Nov; 32(6):2061-2068. PubMed ID: 30353992
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
Yancey MF; Merritt DA; Lesman SP; Boucher JF; Michels GM
J Vet Pharmacol Ther; 2010 Apr; 33(2):162-71. PubMed ID: 20444041
[TBL] [Abstract][Full Text] [Related]
8. A retrospective study of proteinuria in dogs receiving toceranib phosphate.
Piscoya SL; Hume KR; Balkman CE
Can Vet J; 2018 Jun; 59(6):611-616. PubMed ID: 29910474
[TBL] [Abstract][Full Text] [Related]
9. In this issue - May 2019: West Nile virus in horses · Treating horses with dexamethasone via nebulisation · Animal hoarding in NSW · Dangers of powdered washing soda for emesis in dogs · Pneumocystis in a dog following toceranib phosphate · Oxalate nephrosis in koalas.
Jackson AE
Aust Vet J; 2019 May; 97(5):129-130. PubMed ID: 31025324
[No Abstract] [Full Text] [Related]
10. Phosphorylated KIT as a predictor of outcome in canine mast cell tumours treated with toceranib phosphate or vinblastine.
Thamm DH; Weishaar KM; Charles JB; Ehrhart EJ
Vet Comp Oncol; 2020 Jun; 18(2):169-175. PubMed ID: 31365175
[TBL] [Abstract][Full Text] [Related]
11. Presumptive primary intrathoracic mast cell tumours in two dogs.
Cartagena-Albertus JC; Moise A; Moya-García S; Cámara-Fernández N; Montoya-Alonso JA
BMC Vet Res; 2019 Jun; 15(1):204. PubMed ID: 31208404
[TBL] [Abstract][Full Text] [Related]
12. Pneumocystis carinii pneumonia in a Yorkshire terrier dog.
Cabañes FJ; Roura X; Majó N; Bragulat MR; Domingo M
Med Mycol; 2000 Dec; 38(6):451-3. PubMed ID: 11204883
[TBL] [Abstract][Full Text] [Related]
13. Palmar-plantar erythrodysesthesia syndrome resulting from toceranib phosphate in a dog with apocrine gland anal sac adenocarcinoma: a case report.
Kim E; Kim SS; Ryu MO
J Vet Sci; 2023 Nov; 24(6):e76. PubMed ID: 37904638
[TBL] [Abstract][Full Text] [Related]
14. Combination toceranib and lomustine shows frequent high grade toxicities when used for treatment of non-resectable or recurrent mast cell tumours in dogs: A European multicentre study.
Bavcar S; de Vos J; Kessler M; de Fornel P; Buracco P; Murphy S; Hirschberger J; Argyle DJ
Vet J; 2017 Jun; 224():1-6. PubMed ID: 28697868
[TBL] [Abstract][Full Text] [Related]
15. Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study.
Wouda RM; Hocker SE; Higginbotham ML
Vet Comp Oncol; 2018 Mar; 16(1):E52-E60. PubMed ID: 28799187
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.
Bernabe LF; Portela R; Nguyen S; Kisseberth WC; Pennell M; Yancey MF; London CA
BMC Vet Res; 2013 Sep; 9():190. PubMed ID: 24079884
[TBL] [Abstract][Full Text] [Related]
17. Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study.
Chon E; McCartan L; Kubicek LN; Vail DM
Vet Comp Oncol; 2012 Sep; 10(3):184-93. PubMed ID: 22235941
[TBL] [Abstract][Full Text] [Related]
18. Response and outcome following toceranib phosphate treatment for stage four anal sac apocrine gland adenocarcinoma in dogs: 15 cases (2013-2017).
Elliott JW
J Am Vet Med Assoc; 2019 Apr; 254(8):960-966. PubMed ID: 30938616
[TBL] [Abstract][Full Text] [Related]
19. Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011-2018.
Lew FH; McQuown B; Borrego J; Cunningham S; Burgess KE
Vet Comp Oncol; 2019 Dec; 17(4):465-471. PubMed ID: 31069932
[TBL] [Abstract][Full Text] [Related]
20. Radiographic aspects of Pneumocystis carinii pneumonia in the miniature Dachshund.
Kirberger RM; Lobetti RG
Vet Radiol Ultrasound; 1998; 39(4):313-7. PubMed ID: 9710133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
